Coca-Cola Femsa S.A. de C.V.

  • ID: 1771045
  • Standard & Poors

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Dominant soft-drink market share, Coca-Cola Co.'s equity participation, and Strategic importance to the Coke system. Highly competitive environment, and Foreign-currency exposure. The ratings for Coca-Cola FEMSA S.A. de C.V. (KOF) reflect the company's dominant soft-drink market share in its franchise territories in Mexico and Argentina, relative cash flow diversification, Coca-Cola Co.'s (KO) 30%-equity participation in KOF, and the company's strategic importance to the Coke system in Latin America. These factors are partially offset by a highly competitive environment, Coca-Cola FEMSA's moderately aggressive financial profile, and foreign-currency exposure related to its dollar-denominated debt. As the largest soft-drink bottler in Mexico and Argentina, KOF represents approximately 14% of KO's total volume in Latin American and 27% of total volume in Mexico. The...

Companies mentioned in this report are: Coca-Cola Femsa, S.A.B. de C.V.
Action: Review

Note: Product cover images may vary from those shown

Coca-Cola Femsa, S.A.B. de C.V.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.